{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:34:47Z","timestamp":1760132087580},"reference-count":25,"publisher":"Hindawi Limited","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2814,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1742-1241.2007.01531.x","type":"journal-article","created":{"date-parts":[[2010,2,2]],"date-time":"2010-02-02T10:07:21Z","timestamp":1265105241000},"page":"152-156","source":"Crossref","is-referenced-by-count":20,"title":["Challenging the equipotency calculation for transdermal buprenorphine: four case studies"],"prefix":"10.1155","volume":"62","author":[{"given":"R.","family":"Likar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Krainer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Sittl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2007,12,18]]},"reference":[{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0304-3959(95)00017-M","article-title":"Validation of World Health Organisation Guidelines for cancer pain relief: a 10-year prospective study","volume":"63","author":"Zech","year":"1995","journal-title":"Pain"},{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2165\/00003495-199142020-00005","article-title":"Treatment principles for the use of opioids in pain of nonmalignant origin","volume":"42","author":"Schug","year":"1991","journal-title":"Drugs"},{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB3|cit3","first-page":"163","article-title":"Opioid equianalgesic conversion: the right dose","volume":"5","author":"Brant","year":"2001","journal-title":"Clin J Oncol Nurs"},{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0029-6465(02)00094-4","article-title":"The use of long-acting opioids in chronic pain management","volume":"38","author":"Vallerand","year":"2003","journal-title":"Nurs Clin North Am"},{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0885-3924(97)00082-1","article-title":"Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy and quality of life","volume":"13","author":"Ahmedzai","year":"1997","journal-title":"Pain Symptom Manage"},{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ctrv.2006.03.001","article-title":"Opioid switching: a systematic and critical review","volume":"32","author":"Mercadante","year":"2006","journal-title":"Cancer Treat Rev"},{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(99)01310-0","article-title":"Management of cancer pain","volume":"353","author":"Portenoy","year":"1999","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB8|cit8","volume-title":"The Cochrane Library","author":"Quigley","year":"2004"},{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0885-3924(01)00294-9","article-title":"Equianalgesic dose ratios for opioids. A critical review and proposals for long-term dosing","volume":"22","author":"Pereira","year":"2001","journal-title":"J Pain Symptom Manage"},{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2174\/1381612043453027","article-title":"The orvinols and related opioids: high affinity ligands with diverse efficacy profiles","volume":"10","author":"Lewis","year":"2004","journal-title":"Curr Pharm Des"},{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB11|cit11","volume-title":"Transtec\u00ae Summary of Product Characteristics","author":"Gr\u00fcnenthal GmbH","year":"2003"},{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB12|cit12","first-page":"7","article-title":"Transdermal therapeutic systems in pain management: practical hints for application","volume":"24","author":"Sturm","year":"2003","journal-title":"Krankenhauspharmazie"},{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clinthera.2005.02.012","article-title":"Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study","volume":"27","author":"Sittl","year":"2005","journal-title":"Clin Ther"},{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0140-6736(96)09024-1","article-title":"Randomised, double-blind, active-controlled crossover trial of intravenous fentanyl in neuropathic pain","volume":"349","author":"Dellemijn","year":"1997","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1212\/WNL.50.6.1842","article-title":"Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy","volume":"50","author":"Harati","year":"1998","journal-title":"Neurology"},{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0304-3959(99)00079-2","article-title":"Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial","volume":"83","author":"Sindrup","year":"1999","journal-title":"Pain"},{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1056\/NEJMoa021420","article-title":"Oral opioid therapy for chronic peripheral and central neuropathic pain","volume":"348","author":"Rowbotham","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1191\/096813099669853099","article-title":"Signal transduction in neuropathic pain, with special emphasis on the analgesic role of opioids. Part II: moving basic science towards a new pharmacotherapy","volume":"6","author":"McCormack","year":"1999","journal-title":"Pain Rev"},{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00002508-200309000-00002","article-title":"Clinical application of opioid equianalgesic data","volume":"19","author":"Gammaitoni","year":"2003","journal-title":"Clin J Pain"},{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G","article-title":"Opioid rotation for cancer pain. Rationale and clinical aspects","volume":"86","author":"Mercadante","year":"1999","journal-title":"Cancer"},{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB21|cit21","first-page":"19","volume-title":"Buprenorphine: Combating Drug Abuse with a Unique Opioid","author":"Rothman","year":"1995"},{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/j.1476-5381.1995.tb13346.x","article-title":"Subgroups among \u03bc-opioid receptor agonists distinguished by ATP-sensitive K+ channel-acting drugs","volume":"114","author":"Oca\u00f1a","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/0091-3057(94)90258-5","article-title":"A comparison of the antinociceptive effects of opioid agonists in neonatal and adult rats in phasic and tonic nociceptive tests","volume":"49","author":"McLaughlin","year":"1994","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1213\/01.ANE.0000145066.06538.20","article-title":"Transdermal buprenorphine for treating nociceptive and neuropathic pain: four case studies","volume":"100","author":"Likar","year":"2005","journal-title":"Anesth Analg"},{"key":"10.1111\/j.1742-1241.2007.01531.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0885-3924(00)00228-1","article-title":"Opioid poorly responsive cancer pain. Part 1. Clinical considerations","volume":"21","author":"Mercadante","year":"2001","journal-title":"J Pain Symptom Manage"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2007.01531.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2007.01531.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:07:03Z","timestamp":1643350023000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2007.01531.x"}},"subtitle":["TDS buprenorphine equipotency ratio"],"short-title":[],"issued":{"date-parts":[[2007,12,18]]},"references-count":25,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2007.01531.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12,18]]}}}